Diabetic Macular Edema

Diabetic retinopathy can cause swelling of the center of the retina, the macula, and vision loss.

What is a Diabetic Macular Edema

Diabetic macular edema is swelling in the retina associated with diabetes. This swelling can blur and distort the vision. The swelling occurs because the walls of the small blood vessels are progressively more damaged in diabetes, and there is leakage of blood and fluid into the cells of the retina. There are a variety of options to treat diabetic macular edema. The oldest treatment is laser for retinal swelling. It has been studied for decades and has been shown to be safe and effective. As with all treatments, it is not curative, and it is not without risk, but laser is one of the safest things that we do in diabetic retinal care. Other newer treatments for diabetic retinal swelling have been shown to improve vision even more than laser in some cases, and have also been shown to be safe and effective in large modern trials. These treatments are a variety of injections given into the eye in the office, and they are sometimes given alone and sometimes given with laser in addition. There are two major classes of injections used in diabetic macular edema, and those are small molecule injections and corticosteroid injections. The injections work in different ways to reduce the leakage and swelling in the retina, and sometimes the different types of injections are both used. The injections are administered under local anesthesia, and are often relatively well-tolerated by patients. Injections are also amongst the safest procedures performed in the retinal clinic, and the specific risks and benefits of injections will be discussed by your doctor. Most patients with blurred vision from diabetic macular edema enjoy an improvement in vision with treatment. Often, treatment to maintain vision is ongoing, and the long-term treatment plan is individualized to each specific patient in our practice.

What is a Laser?

When diabetic macular edema is caused by focal areas of leakage, laser treatment can be helpful. Studies were done in the 1980's validating the use of laser to reduce the risk of vision loss and improve vision in patients with diabetic macular edema. The advantage of laser of intravitreal injections is that laser treatment usually only needs to be repeated a few times. Intravireal injections are given monthly. The disadvantage of laser, is that it does not improve vision as much as intravitreal injections do when the center of the macula is swollen. Many physicians will use both laser and intravitreal injections depending on the area of the macula that is swollen and the findings on examination and testing.

Lucentis for Diabetic Macular Edema

Monthly Lucentis therapy is helpful for patients with diabetic macular edema. With laser only, about 15 percent of patients have substantial visual improvement at 2 years. With Lucentis therapy, about 40 percent of patients have a substantial improvement in visual acuity. Subsequent studies have shown that ongoing monthly treatment is usually not necessary to maintain the visual benefit.

Diabetic Macular Edema NEWS

Below are current articles from a Google News Feed on Diabetic Macular Edema

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

KalVista To Pioneer Plasma Kallikrein Inhibitor Therapy For Diabetic Macular Edema
Seeking Alpha
Anti-VEGF therapy for diabetic macular edema (DME) is heralded as a "miracle treatment". Granted, but there exists a significant subset of minimally- or non-responsive patients. DME lacks a concrete second-line treatment for minimally- or non ...

and more »

Characteristics of diabetic macular edema on optical coherence tomography may change over time or after treatment
Dove Medical Press
Purpose: To investigate optical coherence tomography (OCT) characteristics in diabetic macular edema (DME) over time and after treatment. Patients and methods: OCT morphological features in DME eyes treated with ranibizumab with at least 1 year of ...


Risuteganib complements anti-VEGF treatment for diabetic macular edema
VIENNA — Integrin inhibitor risuteganib was effective in complementing the anti-VEGF pathway when administered sequentially to an anti-VEGF drug in patients with diabetic macular edema, according to the results of the DEL MAR phase 2b trial. “Positive ...

The efficacy and safety of aflibercept and conbercept in diabetic macular edema
Dove Medical Press
Abstract: Diabetic macular edema (DME) has shown an increasing prevalence during the past years and is the leading cause of diabetic retinopathy blindness. Traditional treatment modalities include laser and corticosteroid therapy, which, however ...

Pulmonology Advisor

CPAP for OSA Does Not Improve Diabetic Macular Edema or Visual Acuity
Pulmonology Advisor
Continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea (OSA) in patients with type 2 diabetes mellitus (T2DM) and diabetic macular edema (DME) did not improve visual acuity compared with usual care alone, according to the ...

Case Report on DME
MedPage Today
Diabetic macular edema (DME) is responsible for most of the visual impairment that affects people with diabetes, and can occur at any stage of diabetic retinopathy. DME causes blurred vision, floaters, double vision, and gradual deterioration of ...

Endocrinology Advisor

Deep Learning Algorithm Efficiently Detects Vision-Threatening Diabetic Retinopathy
Endocrinology Advisor
Researchers developed an algorithm in an effort to better detect forms of vision-threatening referable diabetic retinopathy (preproliferative, diabetic macular edema, or both). They tested the deep learning algorithm on 71,043 retinal images and a ...

Dexamethasone for unresponsive diabetic macular oedema: Optical coherence tomography biomarkers
MD Linx
Researchers assessed the impacts of intravitreal dexamethasone implant (DEX) in patients with diabetic macular oedema (DME) unresponsive to ranibizumab treatment, in relation to the inflammatory optical coherence tomography (OCT) retinal features, ...

Oxurion NV Business Update - Q3 2018
Associated Press (press release) (blog)
Shareholders' Approval and Launch of Oxurion NV as new Company Name. First patient enrolled in Phase 1 study evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME). First Patient enrolled in Phase 2 ...

and more »

MD Magazine

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses
MD Magazine
In 2014, a different team of researchers performed a similar study looking at patients with diabetic macular edema (DME). In that study, 96 patients with DME were given spectral domain-optical coherence tomography (SD-OCT) at baseline, 4 months, and 8 ...

Opthea to Host Wet AMD and Diabetic Macular Edema Key Opinion Leader Forum in New York City
GlobeNewswire (press release)
MELBOURNE, Australia, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a developer of novel biologic therapies for the treatment of eye diseases, is pleased to announce that it will host a symposium focused on next generation treatments ...

and more »

Two Treatments, Similar Outcomes in Diabetic Retinopathy
MedPage Today
Combining the two treatments might be the best strategy for some patients, such as those who have diabetic retinopathy and associated macular edema. The goal would be to minimize the side effects of either treatment. Khurana said prospective studies ...

The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg ...
Dove Medical Press
Purpose: There are little or no published data comparing the outcomes of ILUVIEN® (0.19 mg fluocinolone acetonide [FAc]) and OZURDEX® (0.7 mg dexamethasone [DEX]) implants in patients with diabetic macular edema (DME), and this case sought to ...


Diabetic Vascular Complications Clinical Practice Consensus Guidelines (2018)
... and intravitreal injections of anti–vascular endothelial growth factor (VEGF) agents reduce the rate of vision loss for individuals in vision-threatening stages of retinopathy (severe nonproliferative retinopathy or worse and/or diabetic macular ...

Phase 3 trials to focus on Port Delivery System for AMD, faricimab for DME
Genentech and Roche announced the initiation of three large phase 3 clinical trials evaluating the Port Delivery System with ranibizumab to treat wet age-related macular degeneration and faricimab to treat diabetic macular edema, according to company ...

Diabetic Macular Edema Treatment Market: Market Share, Industry Analysis, Market Size and Outlook 2026
Tampa Bay Review
This report gives a complete survey of the Diabetic Macular Edema Treatment market in the US and its state as of 2018. It gives a comprehensive analysis of the industry, its dynamics, and structure. Market Insights: The exact disease etiology of ...

Contemporary Clinic

Diabetic Eye Exams: Why They Matter
Contemporary Clinic
Diabetes can result in vision problems, so it is important to closely monitor patients through comprehensive eye examinations. Unfortunately, diabetic eye disease may cause vision loss and blindness. Diabetic eye disease is a group of conditions that ...

and more »

Latest Market Reports By Abhishek Budholiya (press release) (blog)

Diabetic Macular Edema Market Predicted to Surpass US$ 4100 Mn by 2027
Latest Market Reports By Abhishek Budholiya (press release) (blog)
Future Market Insights forecasts the global diabetic macular edema market to grow from nearly US$ 3,710 Mn in 2017 to over US$ 4,100 Mn by 2027 end. This represents a CAGR of 1.1% over the forecast period of 2017– 2027. North America is projected to ...
Diabetic Macular Edema Treatment Market Research: Global Industry Analysis, Trends, Market Size, Share and ...Tampa Bay Review

all 2 news articles »


This World Sight Day, let's discuss retinal health: 5 dos and don'ts for healthy eyes
Times Now
While eye diseases related to cornea like cataract are easily recognised, people fail to recognise retinal diseases like age-related macular degeneration (AMD) and diabetic macular edema (DME). Of the various retinal disorders, AMD and DME are two ...
World Sight Day- All you need to know about retina healthBusiness Standard
1.5m people in the UK affected by macular disease, new figures revealAOP

all 18 news articles »

The Straits Times

Young diabetics at higher risk of chronic kidney disease: Study
The Straits Times
At 18, David was diagnosed with Type 2 diabetes. Within three years, he had macular oedema, a diabetic eye disease linked to leaking blood vessels, which left fluid accumulating in part of his retina. David was told that if the condition was left ...

Find Market Research By Abhishek Budholiya (press release) (blog)

Global Diabetic Macular Edema Treatment Market to Witness Soaring Growth During 2017-2025
Find Market Research By Abhishek Budholiya (press release) (blog)
Diabetic macular edema (DME) is characterized by accumulation of fluid in the macula – a part of retina responsible for vision. Accumulation may cause by leakage of plasma constituents into the surrounding, consequently leading to edema. Diabetic ...


FDA nod for EyePoint's Yutiq eye implant fails to lift shares, down almost a third since approval
Seeking Alpha
Uber-bull H.C. Wainwright believes the selloff is misguided (BUY/$4.50) considering that it is similar to Alimera Sciences' (ALIM +2.6%) ILUVIEN (fluocinolone acetonide intravitreal implant), approved by the FDA in September 2014 for diabetic macular ...
B. Riley Boosts Eyepoint Pharmaceuticals (EYPT) Price Target to $6.00Marea Informative (blog)

all 8 news articles »

Fairfield Current

Clearside Biomedical Appoints Veteran Supply Chain Executive, Thomas Crawford, as Vice President, Supply Chain
Associated Press (press release) (blog)
Clearside's pipeline includes advanced and pre-clinical product candidates in diseases where macular edema is a common complication, including uveitis, retinal vein occlusion (“RVO”) and diabetic macular edema (“DME”). Clearside's most advanced ...
Clearside Biomedical (CLSD) Stock Price Down 6.8%Fairfield Current

all 10 news articles »

Euretina Lecture focuses on global challenges of diabetic retinopathy
As for diabetic retinopathy, it is expected to reach 150 million cases by 2030, 30 million of which will develop diabetic macular edema. One major challenge, Tien said, is the “gap in awareness.” More than 75% of patients with DR and 50% of patients ...

BLOG: Putting the 'me' in the treatment of CME
Healio (blog)
Patients who have pre-existing diabetic macular edema or severe diabetic retinopathy are much more prone to developing pseudophakic CME and need to be treated before undergoing cataract surgery. Perioperative complications such as vitreal loss, iris ...

Fairfield Current

Regeneron Pharmaceuticals Inc (REGN) Stake Lowered by Tiaa Fsb
Fairfield Current
The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following ...
Regeneron Pharmaceuticals Inc (REGN) Holdings Cut by Schroder ...BharataPress
United Services Automobile Association Buys 18,886 Shares of ...XNewsPress
Regeneron Pharmaceuticals, Inc. (REGN) Analysts See $5.03 EPSThe Cardinal Weekly (press release)
all 52 news articles »

Trade Market Research

Diabetic Macular Edema Treatment Market 2018 Recent Developments, Major Regions, Top Players, Opportunities in ...
Trade Market Research
Diabetic Macular Edema Treatment Market report delivers a detailed study with present and upcoming opportunities, manufacturers, regional analysis, segmentation by type & applications and the actual process of whole Diabetic Macular Edema Treatment ...
Diabetic Macular Edema Treatment Market 2018-2022: Developments by Regions, Vendors, Types, Applicationsmarketresearchday.com
Diabetic Macular Edema Treatment Market Scope, Overview, Growth, Supply Demand and Shortage, Trends, Demand ...theperfectinvestor.com

all 4 news articles »


Global Diffuse Diabetic Macular Edema Market 2017: Business Analysis, Scope, Size, Trends, Demand, Overview ...
The Diffuse Diabetic Macular Edema Market Report covers vital and needful information which explores the essential data,which is helpful For analysts, industry specialists and other key individuals to self-investigated the market condition. The Report ...
Global Diabetic Macular Edema Therapeutics Market is estimated to Grow at the Highest Growth Rate till 2023MilTech

all 3 news articles »

Hemochromatosis causes overabsorption of iron
Sarasota Herald-Tribune
Dear B.A.: Injections in the eye for diabetics usually are given as a treatment for proliferative diabetic retinopathy or for diabetic macular edema. The injections, any of three different inhibitors of vascular endothelial growth factor, work by ...

and more »

Trade Market Research

Global Diabetic Macular Edema Market 2018 Research for Competitor Information and Insights to Formulate Effective ...
Trade Market Research
The prime objective of Diabetic Macular Edema Market- Pipeline Review, H2 2018, Is to give a Basic information about the global therapeutic landscape of Diabetic Macular Edema, Key players involved with pipeline review and targeted therapeutics ...

and more »
» Load more